Crucell N.V.
Below you will find information from the register publication of inside information. The information has been provided by the organisation.
Registration date
03 jan 2008 - 07:59
Statutory name
Crucell N.V.
Title
Crucell Enters Agreement with Sanofi Pasteur for Next-generation Biologicals against Rabies
Comments
Exclusive agreement for rabies monoclonal antibodies
to fight fatal disease
Leiden, The Netherlands, 3 January 2008 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today announced that it has signed an exclusive collaboration and commercialization agreement with sanofi pasteur, the vaccines division of sanofi-aventis Group, for Crucell’s rabies monoclonal antibodies, the next-generation rabies biologicals to be used in association with rabies vaccine for post-exposure prophylaxis against this fatal disease.
Under the terms of the agreement, Crucell will continue to perform the development activities. Crucell will be responsible for the manufacturing of the final product and will retain exclusive distribution rights in Europe, co-exclusive distribution rights in China and the rights to sell to supranational organizations such as UNICEF. Crucell will receive a payment of € 10 million following the execution of the agreement, will be eligible for milestone payments of up to € 66.5 million and will receive an undisclosed percentage on sales of the final product by sanofi pasteur.
Crucell has developed a combination of two rabies monoclonal antibodies that has shown favorable results comparable to current immunoglobulin products. Phase I clinical trials demonstrated that the antibody product is well tolerated, provides the expected immediate passive neutralizing activity and that it can be safely administered in combination with a rabies vaccine without interfering with the vaccine’s ability to induce an active immunity. The program has been granted a Fast Track designation by the Food and Drug Administration’s (FDA) Department of Health and Human Services. Crucell expects to enter phase II clinical trials in the first half of 2008. Peak sales for Crucell’s rabies antibody cocktail are expected to exceed US$ 300 million.
Sanofi pasteur is the worldwide market leader in providing biologicals for pre- and post-exposure prop
Date last update: 22 July 2025